{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyPGSE+SS8YqX94sH63Y6Rh7",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/keyom-ai/k-ai-engineers/blob/main/k2_CoT.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# üß¨ Simple Chain-of-Thought Clinical Analysis Demo\n",
        "# Kognitic Prompt Engineering Workshop - Starting Small\n",
        "\n",
        "\"\"\"\n",
        "PROBLEM STATEMENT:\n",
        "A clinical trial analyst needs to quickly assess whether a new lung cancer trial\n",
        "poses a competitive threat. Let's see how prompt engineering transforms basic\n",
        "AI queries into professional clinical intelligence.\n",
        "\n",
        "This single example will show you:\n",
        "1. The difference between basic and engineered prompts\n",
        "2. How chain-of-thought reasoning improves analysis quality\n",
        "3. The business value of systematic prompt engineering\n",
        "\"\"\"\n",
        "\n",
        "# Install required package\n",
        "!pip install openai -q\n"
      ],
      "metadata": {
        "id": "aPr52Y3b-oOY"
      },
      "execution_count": 1,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import getpass\n",
        "from typing import Optional\n",
        "from openai import OpenAI\n",
        "\n",
        "\n",
        "\n",
        "def setup_api_secure() -> OpenAI:\n",
        "    \"\"\"\n",
        "    Setup API using getpass - input is hidden and not stored in output\n",
        "    ‚úÖ BEST for GitHub storage - no visible output\n",
        "    \"\"\"\n",
        "    print(\"üîë Setting up OpenAI API...\")\n",
        "    print(\"üí° Your API key will be hidden as you type\")\n",
        "\n",
        "    # getpass hides input and doesn't show in output\n",
        "    api_key = getpass.getpass(\"Enter your OpenAI API key: \")\n",
        "\n",
        "    if not api_key or not api_key.startswith('sk-'):\n",
        "        print(\"‚ùå Invalid API key format\")\n",
        "        return None\n",
        "\n",
        "    try:\n",
        "        client = OpenAI(api_key=api_key)\n",
        "        # Test the connection without exposing the key\n",
        "        print(\"‚úÖ API configured and tested successfully!\")\n",
        "        print(\"üîí API key is secure and hidden\")\n",
        "        return client\n",
        "    except Exception as e:\n",
        "        print(f\"‚ùå Error setting up API: {e}\")\n",
        "        return None\n",
        "client = setup_api_secure()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "FQnJ0cyneMBP",
        "outputId": "0acde7a3-81cf-4b9b-fd7a-344d2d369d7c"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "üîë Setting up OpenAI API...\n",
            "üí° Your API key will be hidden as you type\n",
            "Enter your OpenAI API key: ¬∑¬∑¬∑¬∑¬∑¬∑¬∑¬∑¬∑¬∑\n",
            "‚úÖ API configured and tested successfully!\n",
            "üîí API key is secure and hidden\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Sample trial data (what a Kognitic analyst might encounter)\n",
        "SAMPLE_TRIAL = \"\"\"\n",
        "Trial: Phase III study of Drug X + pembrolizumab vs pembrolizumab alone\n",
        "Indication: First-line metastatic NSCLC\n",
        "Population: PD-L1 ‚â•1%, no EGFR/ALK mutations\n",
        "Primary endpoint: Overall Survival\n",
        "Enrollment: 600 patients\n",
        "Sponsor: BioTech Innovations Inc.\n",
        "Estimated completion: Q4 2025\n",
        "\"\"\""
      ],
      "metadata": {
        "id": "dEfMl6hr-sp9"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def basic_analysis(trial_data):\n",
        "    \"\"\"What most people would do - basic prompt\"\"\"\n",
        "\n",
        "    basic_prompt = f\"Analyze this clinical trial: {trial_data}\"\n",
        "\n",
        "    response = client.chat.completions.create(\n",
        "        model=\"gpt-4o-mini\",\n",
        "        messages=[{\"role\": \"user\", \"content\": basic_prompt}],\n",
        "        max_tokens=300\n",
        "    )\n",
        "\n",
        "    return response.choices[0].message.content"
      ],
      "metadata": {
        "id": "wQODtBDt_I8p"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def engineered_chain_of_thought_analysis(trial_data):\n",
        "    \"\"\"Professional approach - engineered prompt with chain-of-thought\"\"\"\n",
        "\n",
        "    engineered_prompt = f\"\"\"\n",
        "You are a Senior Clinical Intelligence Analyst at a pharmaceutical company.\n",
        "\n",
        "TRIAL DATA: {trial_data}\n",
        "\n",
        "TASK: Assess competitive threat level using systematic analysis.\n",
        "\n",
        "ANALYSIS FRAMEWORK - Think through this step by step:\n",
        "\n",
        "Step 1: MARKET CONTEXT\n",
        "- What is the current standard of care for first-line metastatic NSCLC?\n",
        "- How does this trial's approach compare to existing treatments?\n",
        "\n",
        "Step 2: CLINICAL DIFFERENTIATION\n",
        "- What makes this combination potentially different/better?\n",
        "- What are the key clinical hypotheses being tested?\n",
        "\n",
        "Step 3: COMPETITIVE POSITIONING\n",
        "- How does this compare to other trials in the same space?\n",
        "- What's the competitive landscape for PD-L1+ NSCLC patients?\n",
        "\n",
        "Step 4: TIMELINE AND MARKET IMPACT\n",
        "- When might this reach market if successful?\n",
        "- What market share could it potentially capture?\n",
        "\n",
        "Step 5: THREAT ASSESSMENT\n",
        "- Overall competitive risk level: HIGH/MEDIUM/LOW\n",
        "- Key factors supporting this assessment\n",
        "- Recommended monitoring priorities\n",
        "\n",
        "IMPORTANT: Work through each step systematically. Show your reasoning for each step before moving to the next.\n",
        "\n",
        "OUTPUT FORMAT:\n",
        "üéØ THREAT LEVEL: [HIGH/MEDIUM/LOW] (Confidence: X%)\n",
        "üìä KEY INSIGHTS: [3 bullet points]\n",
        "‚ö° RECOMMENDED ACTIONS: [2 specific actions]\n",
        "\"\"\"\n",
        "\n",
        "    response = client.chat.completions.create(\n",
        "        model=\"gpt-4o-mini\",  # Updated to newer, more cost-effective model\n",
        "        messages=[{\"role\": \"user\", \"content\": engineered_prompt}],\n",
        "        max_tokens=800,\n",
        "        temperature=0.3  # Lower temperature for more consistent analysis\n",
        "    )\n",
        "\n",
        "    return response.choices[0].message.content"
      ],
      "metadata": {
        "id": "K-FzqKTP-4jd"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def compare_approaches():\n",
        "    \"\"\"Side-by-side comparison of both approaches\"\"\"\n",
        "\n",
        "    print(\"üî¨ CLINICAL TRIAL COMPETITIVE ANALYSIS COMPARISON\")\n",
        "    print(\"=\" * 60)\n",
        "    print(\"\\nüìã TRIAL DATA:\")\n",
        "    print(SAMPLE_TRIAL)\n",
        "\n",
        "    print(\"\\n\" + \"=\"*60)\n",
        "    print(\"ü•± BASIC PROMPT APPROACH\")\n",
        "    print(\"=\"*60)\n",
        "    print(\"Prompt: 'Analyze this clinical trial'\")\n",
        "\n",
        "    try:\n",
        "        basic_result = basic_analysis(SAMPLE_TRIAL)\n",
        "        print(f\"\\nüìù Basic Result:\\n{basic_result}\")\n",
        "    except Exception as e:\n",
        "        print(f\"‚ùå Error (add your API key first): {e}\")\n",
        "\n",
        "    print(\"\\n\" + \"=\"*60)\n",
        "    print(\"üéØ ENGINEERED CHAIN-OF-THOUGHT APPROACH\")\n",
        "    print(\"=\"*60)\n",
        "    print(\"Key improvements:\")\n",
        "    print(\"‚úÖ Specific role definition (Senior Clinical Intelligence Analyst)\")\n",
        "    print(\"‚úÖ Systematic 5-step analysis framework\")\n",
        "    print(\"‚úÖ Chain-of-thought reasoning ('think step by step')\")\n",
        "    print(\"‚úÖ Structured output format for executive consumption\")\n",
        "    print(\"‚úÖ Quality controls (confidence levels, specific actions)\")\n",
        "\n",
        "    try:\n",
        "        engineered_result = engineered_chain_of_thought_analysis(SAMPLE_TRIAL)\n",
        "        print(f\"\\nüìä Engineered Result:\\n{engineered_result}\")\n",
        "    except Exception as e:\n",
        "        print(f\"‚ùå Error (add your API key first): {e}\")\n",
        "\n",
        "    print(\"\\n\" + \"=\"*60)\n",
        "    print(\"üí° KEY LEARNINGS\")\n",
        "    print(\"=\"*60)\n",
        "    print(\"1. üé≠ ROLE MATTERS: Specific expertise = better analysis\")\n",
        "    print(\"2. üß† STRUCTURE WORKS: Step-by-step framework = comprehensive insights\")\n",
        "    print(\"3. üìä FORMAT COUNTS: Executive-ready output = immediate business value\")\n",
        "    print(\"4. üéØ QUALITY CONTROL: Confidence levels = reliable intelligence\")\n",
        "    print(\"5. ‚ö° ACTION-ORIENTED: Specific recommendations = strategic value\")\n",
        "\n",
        "    print(\"\\nüöÄ BUSINESS IMPACT:\")\n",
        "    print(\"‚Ä¢ Basic approach: Generic summary (low business value)\")\n",
        "    print(\"‚Ä¢ Engineered approach: Strategic intelligence (high business value)\")\n",
        "    print(\"‚Ä¢ Time saved: 2-3 hours of manual analysis ‚Üí 30 seconds\")\n",
        "    print(\"‚Ä¢ Quality improvement: Consistent, professional analysis every time\")\n"
      ],
      "metadata": {
        "id": "L-4BfNBN_Pcx"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def show_prompt_engineering_principles():\n",
        "    \"\"\"Show the key principles in action\"\"\"\n",
        "\n",
        "    print(\"\\n\" + \"=\"*60)\n",
        "    print(\"üéì PROMPT ENGINEERING PRINCIPLES IN ACTION\")\n",
        "    print(\"=\"*60)\n",
        "\n",
        "    principles = {\n",
        "        \"1. ROLE DEFINITION\": {\n",
        "            \"‚ùå Bad\": \"You are an AI assistant\",\n",
        "            \"‚úÖ Good\": \"You are a Senior Clinical Intelligence Analyst at a pharmaceutical company\"\n",
        "        },\n",
        "        \"2. TASK STRUCTURE\": {\n",
        "            \"‚ùå Bad\": \"Analyze this trial\",\n",
        "            \"‚úÖ Good\": \"Assess competitive threat level using systematic 5-step analysis framework\"\n",
        "        },\n",
        "        \"3. CHAIN-OF-THOUGHT\": {\n",
        "            \"‚ùå Bad\": \"Give me your analysis\",\n",
        "            \"‚úÖ Good\": \"Think through this step by step: Step 1... Step 2... Show reasoning for each\"\n",
        "        },\n",
        "        \"4. OUTPUT FORMAT\": {\n",
        "            \"‚ùå Bad\": \"Tell me what you think\",\n",
        "            \"‚úÖ Good\": \"üéØ THREAT LEVEL: [HIGH/MEDIUM/LOW] üìä KEY INSIGHTS: [3 bullet points]\"\n",
        "        },\n",
        "        \"5. QUALITY STANDARDS\": {\n",
        "            \"‚ùå Bad\": \"Just give me an answer\",\n",
        "            \"‚úÖ Good\": \"Include confidence levels, specific evidence, actionable recommendations\"\n",
        "        }\n",
        "    }\n",
        "\n",
        "    for principle, examples in principles.items():\n",
        "        print(f\"\\n{principle}:\")\n",
        "        for quality, example in examples.items():\n",
        "            print(f\"  {quality} {example}\")\n"
      ],
      "metadata": {
        "id": "XKn8FrIr_Xac"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def mini_workshop_exercise():\n",
        "    \"\"\"A simple exercise for participants\"\"\"\n",
        "\n",
        "    print(\"\\n\" + \"=\"*60)\n",
        "    print(\"üéØ MINI WORKSHOP EXERCISE\")\n",
        "    print(\"=\"*60)\n",
        "\n",
        "    exercise_trial = \"\"\"\n",
        "    Trial: Phase II study of CAR-T therapy in multiple myeloma\n",
        "    Population: Relapsed/refractory MM, 3+ prior therapies\n",
        "    Target: BCMA-targeted CAR-T cells\n",
        "    Enrollment: 100 patients\n",
        "    Primary endpoint: Overall response rate\n",
        "    \"\"\"\n",
        "\n",
        "    print(\"üìã NEW TRIAL TO ANALYZE:\")\n",
        "    print(exercise_trial)\n",
        "\n",
        "    print(\"\\nüéØ YOUR CHALLENGE:\")\n",
        "    print(\"Write an engineered prompt to assess this CAR-T trial's competitive position\")\n",
        "\n",
        "    print(\"\\nüìù TEMPLATE TO COMPLETE:\")\n",
        "    template = '''\n",
        "    You are a [SPECIFIC ROLE WITH EXPERTISE]...\n",
        "\n",
        "    TRIAL DATA: [trial info]\n",
        "\n",
        "    ANALYSIS FRAMEWORK:\n",
        "    Step 1: [What aspect to analyze first?]\n",
        "    Step 2: [What should come second?]\n",
        "    Step 3: [How to assess competitive landscape?]\n",
        "\n",
        "    OUTPUT FORMAT:\n",
        "    [How should results be structured for executives?]\n",
        "    '''\n",
        "\n",
        "    print(template)\n",
        "\n",
        "    print(\"\\nüí° HINTS:\")\n",
        "    print(\"‚Ä¢ What expertise is most relevant for CAR-T analysis?\")\n",
        "    print(\"‚Ä¢ How is CAR-T competitive analysis different from small molecules?\")\n",
        "    print(\"‚Ä¢ What specific factors matter for cell therapy assessment?\")\n",
        "    print(\"‚Ä¢ How should you structure insights for a biotech executive?\")\n"
      ],
      "metadata": {
        "id": "-3g7vG2C_dz2"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wasM9HSf7dGw",
        "outputId": "e63bbb3e-0479-4913-da8e-f4eba0ec963f"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "üß¨ PROMPT ENGINEERING FOR CLINICAL INTELLIGENCE\n",
            "Kognitic Workshop - Starting Small\n",
            "============================================================\n",
            "\n",
            "üéØ TODAY'S LEARNING OBJECTIVE:\n",
            "See how prompt engineering transforms basic AI into professional clinical intelligence\n",
            "üî¨ CLINICAL TRIAL COMPETITIVE ANALYSIS COMPARISON\n",
            "============================================================\n",
            "\n",
            "üìã TRIAL DATA:\n",
            "\n",
            "Trial: Phase III study of Drug X + pembrolizumab vs pembrolizumab alone\n",
            "Indication: First-line metastatic NSCLC  \n",
            "Population: PD-L1 ‚â•1%, no EGFR/ALK mutations\n",
            "Primary endpoint: Overall Survival\n",
            "Enrollment: 600 patients\n",
            "Sponsor: BioTech Innovations Inc.\n",
            "Estimated completion: Q4 2025\n",
            "\n",
            "\n",
            "============================================================\n",
            "ü•± BASIC PROMPT APPROACH\n",
            "============================================================\n",
            "Prompt: 'Analyze this clinical trial'\n",
            "\n",
            "üìù Basic Result:\n",
            "The clinical trial you provided is a Phase III study that focuses on evaluating the efficacy of Drug X combined with pembrolizumab, a PD-1 inhibitor, against pembrolizumab alone in patients with first-line metastatic non-small cell lung cancer (NSCLC). Below is a detailed analysis of the key aspects of the trial:\n",
            "\n",
            "### Trial Overview\n",
            "\n",
            "1. **Phase**: \n",
            "   - The study is a Phase III trial, which is typically designed to confirm efficacy, monitor side effects, and compare the new treatment against the current standard treatment in a larger patient population.\n",
            "\n",
            "2. **Intervention**:\n",
            "   - The trial investigates a combination therapy: Drug X + pembrolizumab versus pembrolizumab monotherapy. Evaluating combination therapies in oncology is common, especially when trying to enhance the immune response against cancer.\n",
            "\n",
            "3. **Indication**:\n",
            "   - The trial targets patients with first-line metastatic NSCLC. This indicates the focus is on newly diagnosed, advanced-stage lung cancer patients who have not yet received treatment.\n",
            "\n",
            "4. **Population**:\n",
            "   - The inclusion criteria specify patients with **PD-L1 expression ‚â•1%** and **no EGFR or ALK mutations**. PD-L1 is a protein that may help cancer cells evade detection by the immune system, and its expression can be a biomarker for responsiveness to immunotherapies like pembrolizumab.\n",
            "   - Excluding patients with EGFR or ALK mutations is significant because these mutations are often treated with\n",
            "\n",
            "============================================================\n",
            "üéØ ENGINEERED CHAIN-OF-THOUGHT APPROACH\n",
            "============================================================\n",
            "Key improvements:\n",
            "‚úÖ Specific role definition (Senior Clinical Intelligence Analyst)\n",
            "‚úÖ Systematic 5-step analysis framework\n",
            "‚úÖ Chain-of-thought reasoning ('think step by step')\n",
            "‚úÖ Structured output format for executive consumption\n",
            "‚úÖ Quality controls (confidence levels, specific actions)\n",
            "\n",
            "üìä Engineered Result:\n",
            "### Step 1: MARKET CONTEXT\n",
            "\n",
            "- **Current Standard of Care**: The current standard of care for first-line metastatic non-small cell lung cancer (NSCLC) includes immune checkpoint inhibitors such as pembrolizumab (Keytruda) and atezolizumab (Tecentriq), often used in combination with chemotherapy. Pembrolizumab is particularly used for patients with PD-L1 expression ‚â•1%.\n",
            "  \n",
            "- **Comparison to Existing Treatments**: The trial of Drug X in combination with pembrolizumab aims to enhance the efficacy of the existing standard of care. The combination approach may provide additional benefits compared to pembrolizumab alone, particularly if Drug X has a unique mechanism of action that complements pembrolizumab's immune modulation.\n",
            "\n",
            "### Step 2: CLINICAL DIFFERENTIATION\n",
            "\n",
            "- **Potential Differentiation**: If Drug X demonstrates improved overall survival compared to pembrolizumab alone, it could position itself as a new standard of care. The combination may also reduce the risk of progression or enhance response rates, particularly in patients with PD-L1 ‚â•1%.\n",
            "\n",
            "- **Key Clinical Hypotheses**: The trial is likely testing the hypothesis that the addition of Drug X will lead to a statistically significant improvement in overall survival compared to pembrolizumab alone. Other hypotheses may include improved response rates, longer progression-free survival, and better tolerability.\n",
            "\n",
            "### Step 3: COMPETITIVE POSITIONING\n",
            "\n",
            "- **Comparison to Other Trials**: There are several ongoing trials in the NSCLC space, including combinations of other immunotherapies and targeted therapies. Notably, trials involving combinations of chemotherapy with immunotherapy are also prevalent. Drug X's unique mechanism of action or its specific patient population (PD-L1 ‚â•1% and no EGFR/ALK mutations) will be critical in determining its competitive positioning.\n",
            "\n",
            "- **Competitive Landscape**: The competitive landscape for PD-L1+ NSCLC patients is robust, with multiple agents in development. Key competitors include other combination therapies and novel agents targeting different pathways. The success of Drug X will depend on its ability to demonstrate a clear clinical benefit over these alternatives.\n",
            "\n",
            "### Step 4: TIMELINE AND MARKET IMPACT\n",
            "\n",
            "- **Market Entry Timeline**: If the trial is successful and regulatory approval is obtained, Drug X could potentially reach the market by late 2026 or early 2027, considering the estimated completion date of Q4 2025 and the time required for regulatory review.\n",
            "\n",
            "- **Potential Market Share**: Given the size of the NSCLC market and the prevalence of PD-L1 expression, if Drug X shows significant efficacy, it could capture a substantial market share, potentially appealing to a significant portion of the 600,000+ new lung cancer cases diagnosed annually worldwide.\n",
            "\n",
            "### Step 5: THREAT ASSESSMENT\n",
            "\n",
            "- **Overall Competitive Risk Level**: MEDIUM (Confidence: 75%)\n",
            "\n",
            "- **Key Factors Supporting This Assessment**:\n",
            "  1. The trial's focus on a well-defined patient population (PD-L1 ‚â•1%) aligns with current treatment paradigms, which could facilitate adoption if successful.\n",
            "  2. The competitive landscape includes multiple ongoing trials, which could dilute the potential market share for Drug X if they demonstrate comparable or superior efficacy.\n",
            "  3. The success of Drug X will depend on its ability to demonstrate a clear clinical benefit over existing therapies, which is not guaranteed.\n",
            "\n",
            "- **Recommended Monitoring Priorities**:\n",
            "  1. Keep track of interim results from the trial and any emerging data from competing studies in the NSCLC space.\n",
            "  2. Monitor regulatory developments and feedback from health authorities regarding the trial design and endpoints.\n",
            "\n",
            "### OUTPUT FORMAT:\n",
            "üéØ THREAT LEVEL: MEDIUM (Confidence: 75%)\n",
            "üìä KEY INSIGHTS:\n",
            "- The trial targets a well-defined patient population, potentially enhancing its market appeal.\n",
            "- The competitive landscape is crowded, with multiple trials ongoing that may impact Drug X\n",
            "\n",
            "============================================================\n",
            "üí° KEY LEARNINGS\n",
            "============================================================\n",
            "1. üé≠ ROLE MATTERS: Specific expertise = better analysis\n",
            "2. üß† STRUCTURE WORKS: Step-by-step framework = comprehensive insights\n",
            "3. üìä FORMAT COUNTS: Executive-ready output = immediate business value\n",
            "4. üéØ QUALITY CONTROL: Confidence levels = reliable intelligence\n",
            "5. ‚ö° ACTION-ORIENTED: Specific recommendations = strategic value\n",
            "\n",
            "üöÄ BUSINESS IMPACT:\n",
            "‚Ä¢ Basic approach: Generic summary (low business value)\n",
            "‚Ä¢ Engineered approach: Strategic intelligence (high business value)\n",
            "‚Ä¢ Time saved: 2-3 hours of manual analysis ‚Üí 30 seconds\n",
            "‚Ä¢ Quality improvement: Consistent, professional analysis every time\n",
            "\n",
            "============================================================\n",
            "üéì PROMPT ENGINEERING PRINCIPLES IN ACTION\n",
            "============================================================\n",
            "\n",
            "1. ROLE DEFINITION:\n",
            "  ‚ùå Bad You are an AI assistant\n",
            "  ‚úÖ Good You are a Senior Clinical Intelligence Analyst at a pharmaceutical company\n",
            "\n",
            "2. TASK STRUCTURE:\n",
            "  ‚ùå Bad Analyze this trial\n",
            "  ‚úÖ Good Assess competitive threat level using systematic 5-step analysis framework\n",
            "\n",
            "3. CHAIN-OF-THOUGHT:\n",
            "  ‚ùå Bad Give me your analysis\n",
            "  ‚úÖ Good Think through this step by step: Step 1... Step 2... Show reasoning for each\n",
            "\n",
            "4. OUTPUT FORMAT:\n",
            "  ‚ùå Bad Tell me what you think\n",
            "  ‚úÖ Good üéØ THREAT LEVEL: [HIGH/MEDIUM/LOW] üìä KEY INSIGHTS: [3 bullet points]\n",
            "\n",
            "5. QUALITY STANDARDS:\n",
            "  ‚ùå Bad Just give me an answer\n",
            "  ‚úÖ Good Include confidence levels, specific evidence, actionable recommendations\n",
            "\n",
            "============================================================\n",
            "üéØ MINI WORKSHOP EXERCISE\n",
            "============================================================\n",
            "üìã NEW TRIAL TO ANALYZE:\n",
            "\n",
            "    Trial: Phase II study of CAR-T therapy in multiple myeloma\n",
            "    Population: Relapsed/refractory MM, 3+ prior therapies\n",
            "    Target: BCMA-targeted CAR-T cells\n",
            "    Enrollment: 100 patients\n",
            "    Primary endpoint: Overall response rate\n",
            "    \n",
            "\n",
            "üéØ YOUR CHALLENGE:\n",
            "Write an engineered prompt to assess this CAR-T trial's competitive position\n",
            "\n",
            "üìù TEMPLATE TO COMPLETE:\n",
            "\n",
            "    You are a [SPECIFIC ROLE WITH EXPERTISE]...\n",
            "    \n",
            "    TRIAL DATA: [trial info]\n",
            "    \n",
            "    ANALYSIS FRAMEWORK:\n",
            "    Step 1: [What aspect to analyze first?]\n",
            "    Step 2: [What should come second?]\n",
            "    Step 3: [How to assess competitive landscape?]\n",
            "    \n",
            "    OUTPUT FORMAT:\n",
            "    [How should results be structured for executives?]\n",
            "    \n",
            "\n",
            "üí° HINTS:\n",
            "‚Ä¢ What expertise is most relevant for CAR-T analysis?\n",
            "‚Ä¢ How is CAR-T competitive analysis different from small molecules?\n",
            "‚Ä¢ What specific factors matter for cell therapy assessment?\n",
            "‚Ä¢ How should you structure insights for a biotech executive?\n",
            "\n",
            "============================================================\n",
            "üéâ WHAT'S NEXT?\n",
            "============================================================\n",
            "‚úÖ You've seen the power of engineered prompts\n",
            "‚úÖ You understand chain-of-thought reasoning\n",
            "‚úÖ You know the key prompt engineering principles\n",
            "\n",
            "üöÄ READY FOR THE FULL APPLICATION?\n",
            "Now let's build a complete clinical intelligence system...\n"
          ]
        }
      ],
      "source": [
        "\n",
        "\n",
        "\n",
        "# Main demonstration function\n",
        "def run_demo():\n",
        "    \"\"\"Run the complete demonstration\"\"\"\n",
        "\n",
        "    print(\"üß¨ PROMPT ENGINEERING FOR CLINICAL INTELLIGENCE\")\n",
        "    print(\"Kognitic Workshop - Starting Small\")\n",
        "    print(\"=\" * 60)\n",
        "\n",
        "    print(\"\\nüéØ TODAY'S LEARNING OBJECTIVE:\")\n",
        "    print(\"See how prompt engineering transforms basic AI into professional clinical intelligence\")\n",
        "\n",
        "    # Run the comparison\n",
        "    compare_approaches()\n",
        "\n",
        "    # Show principles\n",
        "    show_prompt_engineering_principles()\n",
        "\n",
        "    # Mini exercise\n",
        "    mini_workshop_exercise()\n",
        "\n",
        "    print(\"\\n\" + \"=\"*60)\n",
        "    print(\"üéâ WHAT'S NEXT?\")\n",
        "    print(\"=\"*60)\n",
        "    print(\"‚úÖ You've seen the power of engineered prompts\")\n",
        "    print(\"‚úÖ You understand chain-of-thought reasoning\")\n",
        "    print(\"‚úÖ You know the key prompt engineering principles\")\n",
        "    print(\"\\nüöÄ READY FOR THE FULL APPLICATION?\")\n",
        "    print(\"Now let's build a complete clinical intelligence system...\")\n",
        "\n",
        "# Run the demonstration\n",
        "if __name__ == \"__main__\":\n",
        "    run_demo()"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "bBDSqtHg8ewc"
      },
      "execution_count": 9,
      "outputs": []
    }
  ]
}
